网络药理学与药代动力学整合策略研究香连丸治疗溃疡性结肠炎的作用机制
本研究采用网络药理学与药代动力学整合策略,探究香连丸中9种定量成分治疗溃疡性结肠炎(UC)的药理机制。网络药理学分析发现9种成分与UC有50个交叉基因,主要调控Th17细胞分化、Jak-Stat和PI3K-Akt等免疫通路;小鼠模型验证香连丸通过抑制Jak2-Stat3通路抑制Th17细胞分化,减轻黏膜炎症;分子对接证实8种成分可与JAK2、HIF-1α和HSP90AB1结合;药代动力学研究显示9种成分在血浆和结肠组织中暴露。
要点
- 香连丸通过抑制Jak2-Stat3通路减少Th17细胞分化,缓解UC黏膜炎症。
- 香连丸中8种成分可与JAK2、HIF-1α和HSP90AB1结合,佐证其通路抑制作用。
- 9种成分在血浆和结肠组织均有暴露,支持其治疗UC的药理效应。
核心结论
- 香连丸治疗UC的机制主要涉及调控Th17细胞分化、Jak-Stat和PI3K-Akt等免疫通路,并通过抑制Jak2-Stat3通路减少Th17细胞分化来减轻黏膜炎症。
研究设计与样本
- 研究采用网络药理学分析9种定量香连丸成分对UC的治疗作用,并通过小鼠UC模型验证Th17细胞分化效应,结合分子对接评估成分与JAK2、STAT3、HIF-1α和HSP90AB1的结合,同时建立UHPLC-MS/MS方法进行药代动力学研究。
主要发现
- 网络药理学揭示9种化合物与UC之间有50个交叉基因,主要富集于Th17细胞分化、Jak-Stat和PI3K-Akt信号通路。
- 小鼠体内验证发现香连丸通过抑制Jak2-Stat3通路抑制Th17细胞分化,从而缓解UC黏膜炎症。
- 分子对接 confirmed 8种化合物能与JAK2、HIF-1α和HSP90AB1结合。
- 药代动力学研究显示9种成分在血浆和结肠组织中有暴露。
临床怎么用
- 香连丸可作为治疗UC的潜在中药选择,其机制涉及抑制Jak2-Stat3通路和Th17细胞分化。
- 临床可考虑将香连丸用于UC患者,尤其关注其免疫调节作用,但需结合辨证论治。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with high morbidity, which leads to poor quality of life. The Xianglian pill (XLP) is a classical Chinese patent medicine and has been clinically proven to be an effective treatment for UC. PURPOSE: The pharmacological mechanism of the key bioactive ingredients of XLP for the treatment of UC was investigated by a network pharmacology and pharmacokinetics integrated strategy. STUDY DESIGN AND METHODS: Network pharmacology was used to analyze the treatment effect of nine quantified XLP ingredients on UC. Key pathways were enriched and analyzed by protein-protein interaction and Kyoto Encyclopedia of Genes and Genomes analyses. The effect of XLP on Th17 cell differentiation was validated using a mouse model of UC. The binding of nine compounds with JAk2, STAT3, HIF-1α, and HSP90AB1 was assessed using molecular docking. A simple and reliable ultra-high-performance liquid chromatography-tandem mass spectrometry method was developed for the simultaneous quantification of nine ingredients from XLP in plasma and applied to a pharmacokinetic study following oral administration. RESULTS: Nine compounds of XLP, including coptisine, berberine, magnoflorine,berberrubine, jatrorrhizine, palmatine, evodiamine, rutaecarpine, and dehydrocostus lactone, were detected. Network pharmacology revealed 50 crossover genes between the nine compoundsand UC. XLP treats UC mainly by regulating key pathways of the immune system, including Th17 cell differentiation, Jak-Stat, and PI3K-Akt signaling pathways. An in vivo validation in mice found that XLP inhibits Th17 cell differentiation by suppressing the Jak2-Stat3 pathway, which alleviates mucosal inflammation in UC. Molecular docking confirmed that eight compounds are capable of binding with JAk2, HIF-1α, and HSP90AB1, further confirming the inhibitory effect of XLP on the Jak2-Stat3 pathway. Moreover, apharmacokinetic study revealed that the nine ingredients of XLP are exposed in the plasma and colon tissue, which demonstrates its pharmacological effect on UC. CONCLUSION: This study evaluates the clinical treatment efficacy of XLP for UC. The network pharmacology and pharmacokinetics integrated strategy evaluation paradigm is efficient in discovering the key pharmacological mechanism of herbal formulae.
引用
- Liu CS, Xia T, Luo ZY, et al. Network pharmacology and pharmacokinetics integrated strategy to investigate the pharmacological mechanism of Xianglian pill on ulcerative colitis. Phytomedicine. 2020. PMID: 33486267. doi:10.1016/j.phymed.2020.153458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。